Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIb pivotal clinical trial of LBL-024 in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

Phase IIb pivotal clinical trial of LBL-024 in Patients With Advanced Solid Tumors

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 06 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LBL-024 (Primary)
  • Indications Solid tumours
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 06 May 2024 New trial record
  • 30 Apr 2024 According to Nanjing Leads Biolabs Co., Ltd. media release, study is led by Professor Shen Lin from Peking University Cancer Hospital, and detailed clinical data will be disclosed during the ASCO Annual Meeting on May 31st to June 4th, 2024.
  • 30 Apr 2024 According to Nanjing Leads Biolabs Co., Ltd. media release, Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approved the Single-Arm Pivotal Clinical Study of LBL-024 for advanced solid tumors .

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top